Pictet Asset Management
NKTR icon

Pictet Asset Management’s Nektar Therapeutics NKTR Stock Holding History

Pictet Asset Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$327K Buy
4,684
+966
+26% +$70.7K ﹤0.01% 1728
2026
Q1 		$268K Buy
+3,718
New +$212K ﹤0.01% 1775

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pictet Asset Management's NKTR Position: Q2 2026 in Review

Pictet Asset Management increased its Nektar Therapeutics (NKTR) stake by 26% in Q2 2026, buying an estimated $70.7K and bringing the position to 4,684 shares worth $327K. The position accounts for ﹤0.01% of the portfolio, ranked #1728.

Pictet Asset Management first reported a position in NKTR in Q1 2026 and has held it in 2 quarters since. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Pictet Asset Management held 4,684 shares of Nektar Therapeutics worth $327K as of Q2 2026.
  • Pictet Asset Management bought 966 Nektar Therapeutics shares in Q2 2026, an estimated $70.7K.
  • Nektar Therapeutics made up ﹤0.01% of Pictet Asset Management's portfolio in Q2 2026, its #1728 holding.
  • Pictet Asset Management first reported a position in Nektar Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.